Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,578.86
-20.4678-1.28%
Number of Gainers:- -
Number of Losers:7
Number of Flat:- -
PE:- -
High:1,598.74
Open:1,598.63
Low:1,577.34
Close:1,599.33
Volume:11.11M
Turnover:934.68M
Market Cap:1.64T
Float Cap:1.58T

Loading ...

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Yesterday

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Yesterday

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Yesterday

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Yesterday

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

GlobeNewswire
·
Yesterday

Patients Switching to Novo Nordisk's Wegovy Pill from Shots Lose More Weight in Real-World Study

Reuters
·
Yesterday

Sino Biopharmaceutical Stock Rises 2.9% in Hong Kong

Dow Jones
·
Yesterday

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

TIPRANKS
·
Yesterday

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

Reuters
·
Yesterday

Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks

THOMSON REUTERS
·
Yesterday

Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Yesterday

Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027

THOMSON REUTERS
·
Yesterday

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Yesterday

Amgen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Novo Says Ozempic Cuts Risk of Major Cardiovascular Events

Reuters
·
Sep 29

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis

TIPRANKS
·
Sep 29

Altimmune Names Richard Menziuso Principal Accounting Officer, Global Controller VP

Reuters
·
Sep 29

Eli Lilly - Zepbound 10 Mg and 15 Mg Show Comparable Adverse Event Discontinuation Rates to Wegovy Hd

THOMSON REUTERS
·
Sep 29